comparemela.com

Page 8 - மிதமான News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vifor Pharma and Cara Therapeutics announce U S FDA acceptance and Priority Review of NDA for KORSUVA* injection in hemodialysis patients with moderate-to-severe pruritus

Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA injection in hemodialysis patients with moderate-to-severe pruritus If approved, KORSUVA injection would be first therapy for treatment of pruritus in hemodialysis patients Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210307005039/en/ Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is 23 August 2021. The FDA stated that currently it is not planning to hold an advisory committee meeting to discuss the application.

Three injured after crash into power pole closed State Highway 5 near Napier

A car crashed into and downed a power pole on State Highway 5, near Napier

Senate nears relief bill votes

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.